<DOC>
	<DOCNO>NCT02361931</DOCNO>
	<brief_summary>The investigative product , develop Remedor , unique gel formulation optimize administration EPO wind bed . This novel formulation show stabilize EPO gel maintain activity long period .</brief_summary>
	<brief_title>Safety Efficacy Novel Topical Formulation Containing Erythropoietin</brief_title>
	<detailed_description>Erythropoietin ( EPO ) show play major role wound heal . EPO safe molecule , commercially available biomolecule basis FDA approve drug treat anemia . EPO known mechanism action chronic wound affect phase wound heal process show promising result experimental animal wound model [ Hamed et al. , 2010 , 2011 ] . In human , topically apply EPO considerably enhance wound heal improve wound condition acute chronic wound [ Bader et al. , 2011 ] . Our study seek extend finding , investigate efficacy EPO treatment diabetic chronic wound human . The investigative product , develop Remedor , unique gel formulation optimize administration EPO wind bed . This novel formulation show stabilize EPO gel maintain activity long period . The Remedor formulation use clinical trial prepare either compound pharmacy approve Israeli Ministry Health , Israeli GMP certify pharmaceutical plant .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients must satisfy follow inclusion criterion include study : 1 . Male female age 18 ; 2 . Diabetes Mellitus type 2 ; 3 . Have single noninfected Diabetic HardtoHeal wound ( ulcers/foot ulcer ) , Wagner grade I II document least 4 week show sign heal despite standard treatment ; 4 . 2 cm2 ≤ Wound area start treatment ≤ 10 cm2 ; 5 . At least moderate blood perfusion affect limb define Ankle Brachial Index ( ABI ) 0.4 &lt; ABI &lt; 0.9 ABI &gt; 1.3 toe pressure &gt; 50 mmHg ; 6 . Undergo current physical examination , reveals clinically significant abnormality , except diabetes diabetic ulcer/wound related condition ; 7 . Be available entire study period , able willing adhere protocol requirement ; 8 . Provide write informed consent prior admission study ; Patients exclude study meet follow exclusion criterion : 1 . Diabetes Mellitus non Type 2 ; 2 . Have glycosylated haemoglobin ( HbA1c ) &gt; 10.0 % ; 3 . Have body mass index ( BMI ) &gt; 40 Kg/m2 ; 4 . Have visible bone exposure wound site ; 5 . Subjects whose study ulcer size decrease 30 % initial standardofcare phase ( pretreatment phase ) ; 6 . Have sign infection wound ( could link raise body temperature ) , abscess , cellulitis , necrosis , erythema , mild drainage know osteomyelitis ; 7 . Have history HIV clinically significant cardiac , gastrointestinal , endocrine , neurological , liver , kidney disease ; 8 . Anemia ( Hemoglobin &lt; 9 g/dL ) White Blood Cells count &gt; 11,000/μL Platelets count &lt; 100,000/μL liver function test &gt; 3 time upper normal lab value Creatinine &gt; 3 mg/dL ; indication malnourishment ( Albumin &lt; 3 g/dL ) ; INR &gt; 2 clinically significant blood urinalysis test per physician 's discretion 9 . Have clinically significant chronic acute illness 4 week prior admission study , except diabetes type2 screening period ; 10 . Patients concomitant medication alter blood glucose level ( e.g . ACE inhibitor , lipid lower agent , etc . ) stable dosage regimen least 4 week prior entry study maintain stable dosage throughout study ; 11 . Malignant disease except Basal Cell Carcinoma Cervical Carcinoma situ ; Chemotherapy treatment severely immunosuppressed reason would limit preclude heal opinion Investigator ; 12 . Females pregnant , lactating , childbearing potential , postmenopausal less 2 year , use medically approve method contraception ( i.e. , oral , transdermal , implanted contraceptive , intrauterine device , diaphragm , condom , abstinence , surgical sterility ) , females test positive bloodbased pregnancy test ; 13 . Participation clinical study use investigational drug within 30 day prior admission study ; 14 . Residing nurse facility and/or bedridden ( unable come receive treatment clinic ) ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>accelerate heal</keyword>
	<keyword>diabetic chronic wound</keyword>
	<keyword>diabetic patient</keyword>
	<keyword>diabetic chronic ulcer</keyword>
	<keyword>Wagner grade II</keyword>
	<keyword>infection</keyword>
	<keyword>necrosis</keyword>
	<keyword>erythema</keyword>
	<keyword>mild drainage</keyword>
</DOC>